Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DARA BioSciences
Raleigh, North Carolina, United Statesdarabiosciences.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
DARA's lead clinical asset was KRN5500 for neuropathic pain in cancer patients, which completed a Phase 2a study and received Fast Track designation from the FDA. The company also launched several oncology support products including Soltamox® (oral tamoxifen), Bionect®, and Gelclair®, all focused on improving quality of life for oncology patients through symptom management and supportive care.
- Therapeutic areas
- GastroenterologyOncologyDermatologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
Helsinn Group of Switzerland – exclusive U.S. commercial rights to GelclairKirin Pharmaceuticals – licensing agreement for drug candidates including KRN5500/Kirin compoundsBayer Pharmaceuticals Corporation – licensing partner
Beyond the preview
Go deeper on DARA BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DARA BioSciences.